Sernova Biotherapeutics Announces Merger with Seraxis to Form BetaNova Biotherapeutics
The Toronto‑listed biotechnology company Sernova Biotherapeutics Inc. (TSX: SVA) has entered into a definitive merger agreement with Seraxis Holdings, Inc. The transaction will create BetaNova Biotherapeutics, Inc., a U.S.‑domiciled, clinical‑stage company focused on a differentiated approach to type‑1 diabetes (T1D) islet‑cell replacement.
Key Terms of the Merger
| Item | Details |
|---|---|
| Merger Structure | Sernova and Seraxis will combine their technologies and businesses, with each shareholder group receiving roughly 50 % ownership in the new entity. |
| Name & Headquarters | BetaNova Biotherapeutics, Inc.; headquartered in Germantown, Maryland, United States. |
| Timeline | Merger completion expected in November 2026, pending shareholder approval. |
| Future Listing | Post‑merger, BetaNova intends to seek a listing on the NASDAQ in Q1 2027, subject to all listing requirements and approvals. |
| Financing | A US$10 million non‑brokered convertible note has been secured from existing insider shareholders of both Sernova and Seraxis. The notes will automatically convert to non‑voting common stock of BetaNova upon completion of the merger. Additional qualified investors may participate until 30 September 2026. |
Strategic Rationale
The merger unites two complementary platforms:
| Platform | Strengths |
|---|---|
| Sernova | Cell‑pouch bio‑hybrid organ technology and cGMP manufacturing for islet‑cell therapy. |
| Seraxis | Stem‑cell‑derived pancreatic islet cells, with proprietary gene‑editing capabilities to reduce immunogenicity. |
Together, the companies will advance a pipeline anchored by the lead product candidate SR‑02—a stem‑cell‑derived, allogeneic islet‑cell therapy designed to work with next‑generation, low‑toxicity immunosuppressants to establish immune tolerance. A follow‑on candidate, SR‑03, incorporates gene edits intended to provide immune evasion, potentially eliminating the need for immunosuppression entirely.
Development Milestones
| Milestone | Target |
|---|---|
| Phase 1/2 Clinical Trial (SR‑02) | First patient dosing anticipated Q1 2027 under an FDA‑cleared IND (NCT07581197). |
| Data Readiness | Clinical data expected by mid‑2027. |
| SR‑03 IND | Submission projected for H2 2027. |
| Manufacturing | cGMP production of SR‑02 and SR‑03 to begin post‑merger. |
| NASDAQ Listing | Readiness aimed for Q1 2027. |
A webinar to provide further details will be held on 11 September 2026 at 10 a.m. EDT, with sessions in Toronto and Germantown, Maryland.
Market Context
Sernova’s shares, listed on the Toronto Stock Exchange and traded over-the-counter, closed at CAD 0.13 on 7 September 2026, within a 52‑week range of CAD 0.10 to CAD 0.20. The company’s market capitalization stands at CAD 41.5 million, and its price‑earnings ratio is ‑3.11. The merger is expected to unlock value by combining Sernova’s manufacturing capabilities with Seraxis’s stem‑cell technology, potentially positioning the new company as a leader in the niche of islet‑cell replacement for type‑1 diabetes.
This article synthesizes publicly available information from news releases dated 8 September 2026 and Sernova Biotherapeutics’ own financial data as of 7 September 2026. No additional data have been introduced beyond the provided sources.
